165 filings
8-K
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
8-K
ABBV
Abbvie Inc
3 Apr 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:06pm
8-K
ABBV
Abbvie Inc
26 Feb 24
Other Events
5:08pm
8-K
ABBV
Abbvie Inc
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
ABBV
Abbvie Inc
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
pkr258yhzfm1x5hk
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
qwecipbpnj4ntx3
5 Jan 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:03pm
8-K
cy8h42u1clqnn i1tt
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
4ggrlqo2ucyw
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
bbc9n2qlude
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
j7vf5np5m
12 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
6bp1n5cu57zbw7kwg 14
4 Oct 23
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:11pm
8-K
u30nwvfe6cf iesq1wbf
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
eeg86ts oyodc0v
6 Jul 23
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:18pm
8-K
jj7y 21itf83s4ur0
29 Jun 23
Departure of Directors or Certain Officers
5:00pm
8-K
09vlyl dr85wfgdxq
10 May 23
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
b3qm9
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
u7hap4
5 Apr 23
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:33pm
8-K
i71mom23qu8s4
28 Mar 23
Entry into a Material Definitive Agreement
4:37pm
8-K
k9s1ail 0yy
9 Feb 23
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
7:55am